AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results